Physician profile
John Robert Balk
NPI 1215371562
$18,928.26
in general payments reported to CMS, 2019-2025
26 companies · $343 in 2025
The $343 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $3,258 · 2021: $646 · 2022: $2,091 · 2023: $1,184 · 2024: $1,307 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,297 · Food and Beverage: $537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,296.76 |
| Food and Beverage | $537.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuvasive, INC. | $7,500.00 | 2019 | |
| Medacta USA, INC. | $5,815.78 | 2020-2025 | Amistem |
| Seaspine Orthopedics Corporation | $1,628.50 | 2019 | |
| Aesculap Implant Systems, LLC | $1,100.70 | 2022-2023 | Activl |
| Rock Medical Orthopedics, INC. | $813.05 | 2020-2022 | |
| Si-Bone, INC. | $805.71 | 2019 | |
| Amgen INC. | $254.70 | 2020-2024 | Evenity |
| Spineology INC. | $187.57 | 2019-2022 | |
| Orthofix Medical, INC. | $160.97 | 2022-2023 | Physio-Stim |
| Janssen Pharmaceuticals, INC | $112.42 | 2023 | Xarelto |
| Jazz Pharmaceuticals INC. | $79.51 | 2020-2021 | |
| Abbvie INC. | $78.41 | 2021-2022 | |
| Conformis, INC. | $73.38 | 2019 | |
| Bioventus LLC | $40.45 | 2021-2023 | Durolane |
| Merck Sharp & Dohme LLC | $36.97 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $34.49 | 2021 | |
| Heron Therapeutics, INC. | $31.24 | 2021-2022 | |
| Novo Nordisk INC | $29.73 | 2020-2021 | |
| Pacira Therapeutics, INC. | $26.88 | 2019-2021 | |
| Globus Medical, INC. | $22.86 | 2025 | Ossifuse, Affirm, Osteocel |
| Abbott Laboratories | $18.73 | 2021 | |
| Theragen, INC. | $18.40 | 2023 | Actastim-S |
| Horizon Therapeutics Plc | $15.07 | 2022 | |
| Trevena, INC. | $14.77 | 2022 | |
| Currax Pharmaceuticals LLC | $14.53 | 2021 | |
| Avanir Pharmaceuticals, INC. | $13.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Balk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.